SBC Medical Group (SBC) Expected to Announce Quarterly Earnings on Friday

SBC Medical Group (NASDAQ:SBC) is projected to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $45.1890 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 27, 2026 at 8:30 AM ET.

SBC Medical Group Stock Up 3.7%

Shares of NASDAQ SBC opened at $3.63 on Friday. The firm has a fifty day simple moving average of $4.20 and a two-hundred day simple moving average of $4.06. SBC Medical Group has a 12 month low of $2.91 and a 12 month high of $5.75. The company has a current ratio of 5.10, a quick ratio of 5.06 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $372.37 million, a PE ratio of 8.85 and a beta of 1.19.

Insider Activity at SBC Medical Group

In other news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $2.12, for a total transaction of $9,376,548.00. Following the sale, the chief executive officer owned 861,600 shares in the company, valued at approximately $1,826,592. The trade was a 83.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 89.47% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock valued at $54,000 after purchasing an additional 8,348 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of SBC Medical Group by 292.0% in the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock worth $51,000 after buying an additional 8,771 shares during the last quarter. Barclays PLC increased its position in SBC Medical Group by 123.7% during the 4th quarter. Barclays PLC now owns 17,779 shares of the company’s stock valued at $77,000 after buying an additional 9,831 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in SBC Medical Group during the 4th quarter valued at approximately $49,000. Finally, Nuveen LLC purchased a new position in SBC Medical Group during the fourth quarter valued at $53,000. 60.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SBC shares. BTIG Research initiated coverage on shares of SBC Medical Group in a research note on Friday, March 6th. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SBC Medical Group has an average rating of “Hold” and a consensus target price of $8.50.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.